陳炯東

CT Chen 2陳炯東  研究員
生技與藥物研究所
Email: ctchen@nhri.edu.tw

 

EDUCATION

  • Ph.D., Pharmaceutics and Pharmaceutical Chemistry, Ohio State University, USA (1992-1997)
  • M.S., Pharmacology, National Yang-Ming University, Taiwan (1986-1988)
  • B.S., Pharmacy, China Medical University, Taiwan (1981-1986)

PROFESSIONAL EXPERIENCES

  • Executive cutive Director, Forum, NHRI (2022/03 (2022/03 – present)
  • 召集人, 農業部「動物科學應用機構監督查核計畫」查核小組 (2023 – present)
  • 諮議委員, 衛生福利部 食品藥物管理署再生醫學諮議小組 (Jan. 2022 – Dec. 2023)
  • 編修委員,衛生福利部 台灣中藥典第五版編修工作小組-中藥製劑小組 (Feb. 2022 – present)
  • 審議委員, 行政院國家發展基金管理會 投資評估審議會 (Jan. 2020 – present)
  • 諮議委員, 衛生福利部 中醫藥司 中藥藥物諮議會中藥製劑小組 (Jan. 2019 – present)
  • 國家文官學院 高階文官培訓 結業 (2018)
  • Federal Executive Institute, FEI (美國聯邦文官學院) 受訓結業 (2018)
  • 諮詢委員, 衛生福利部 中華藥典編修諮詢會 (生物試驗法小組) (Jan. 2017 – present)
  • Director, IBPR, NHRI ( 2017/09-2020/08)
  • Associate Director, IBPR, NHRI (2012/02 – 2017/08)
  • Investigator, IBPR, NHRI (2010/10 – present)
  • Assistant/Associate Investigator, IBPR, NHRI (1999 – 2010)
  • Interim Secretary General, NHRI (2011/03 – 2011/11; 2017/12-2018/01)
  • 查核委員, 農業部「動物科學應用機構監督查核計畫」查核小組 (2005 – present)
  • Director, Laboratory Animal Center, NHRI (2005/03 – 2009/06)
    National Health Research Institutes, Miaoli, Taiwan.
  • Chairman, Institutional Animal Care and Use Committee (IACUC), NHRI (2002 – present)
    National Health Research Institutes, Miaoli, Taiwan.
  • President, The Chinese-Taipei Society of Laboratory Animal Sciences (2016-2019)
  • Vice President, The Chinese-Taipei Society of Laboratory Animal Sciences (2012-2015)
  • Member, Board of Executive Directors, The Chinese-Taipei Society of Laboratory Animal Sciences( 2004-present)
  • Adjunct Professor/Consultant, CMU (2016/08 – present)
  • Jointly Appointed Professor, NCTU (2016/11 – present)
  • Adjunct Professor, Institute of Molecular Medicine, NTHU (2012/08 – present)
  • Adjunct Assistant/Associate Professor,  Institute of Life Science, NDMC (2002 – 2011)
  • Adjunct Assistant Professor, Graduate Institute of Medical Sciences, TMU (2003 – 2012)
  • Member, Board of Directors, Bio 21 Venture Capital Corporation (2003 – 2005/08)
  • Visiting Scientist, Shionogi BioResearch Corp., USA. (1999)
  • Research Associate, James H. Quillen College of Medicine, USA (1997 – 1999)
  • Graduate Research Associate, The Ohio State University, USA. (1992 – 1997)
  • Assistant Research Fellow, Institute of Biological Chemistry, Academia Sinica (1992)
  • Vice Researcher, China Chemical & Pharmaceutical Group (1990 – 1991)
  • Pharmacist, China Chemical & Pharmaceutical Group (1991)

RESEARCH INTERESTS

Dr. Chen considers “Translational Medicine Research” a broad research field covering from basic to clinical researches that ultimately benefit patients in all aspects and, therefore, his research interests have covered a broad spectrum from basic research to drug discovery and development such as the identification of tumor metastasis-associated molecules, establishment of diseased animal models (against cancer, diabetic, and infectious diseases) and discovery and development of new drugs. Dr. Chen is a licensed pharmacist equipped with a broad professional disciplinary scope covering pharmacology, cancer biology, pharmacokinetics, and pharmacodynamics, pharmaceutics, neuroscience, molecular cell biology, laboratory animals, and drug discovery and development. All research activities leading to the discovery and development of clinical therapeutics and advancement of clinical treatments are his major research interests.

RROJECT INVOLVED (近五年)

  • Projects in BP
    1.以CXCR4受體為分子標的之急性心肌梗塞治療藥物開發 (DBPR807), 主持人, 科技部 (2020~2021)
    2.開發促使MYC致癌蛋白質降解的激酶抑制劑 (DBPR728), 共同主持人, 科技 部 (2020~2021)
    3.CSF1R project, 衛福部
    4.Antibodies against neurotensin receptor 1 (NTSR-1) project, 經濟部
    5.抗癌藥物傳輸系統 (DBPR186) project, 經濟部
    6.LHRHR targeting (DBPR376) project, 經濟部
    7.FLT3 (DBPR216) project, 經濟部
    8.isoQC (DBPR22998) project, 衛福部
    9.新冠COVID-19計畫 (Remdesivir), 衛福部
  • Collaborative projects outside BP
    1.IACUC projects, LA -112-PP -03 (2023),  LA -113 -PP -03 , PI, NHRI (2024)
    2.衛生福利政策論壇計畫, 協同主持人, 衛生福利部 (2023)
    3.衛生福利政策論壇計畫, 協同主持人, 衛生福利部 (2022)
    4.Argonaute 2次細胞異質性在腫瘤發展、診斷、治療的角色及應用, 共同主持人, 國科會 (2020-2023)
    5.自我乳化脂質油珠奈米載體用於口服難吸收藥物經淋巴系統以標的胰臟相關疾病, 共同主持人, 科技部 (2020-2021) MAJOR

MAJOR ACCOMPLISHMENTS

  • Dr. Chen has established and led a research team responsible for executing the in vivo pharmacological/toxicological evaluations of and for identifying the drug leads and preclinical development drug candidates discovered in the Institute of Biotechnology and Pharmaceutical Research of the NHRI. Dr. Chen has devoted himself to the new drug discovery and development activities in Taiwan for more than 23 years. A number of drug leads and 16 developmental drug candidates against cancer, diabetic, and infectious have been identified, with the supports from Dr. Chen’s lab, and show promising pharmacological activities and acceptable toxicological profiles in animals.
  • 11 anticancer drug candidates (intravenously active DBPR104/DBPR114/DBPR115/ DBPR807/DBPR186/DBPR376, and orally active DBPR204/DBPR112/DBPR216/ DBPR728/DBPR22998), of which DBPR104 and DBPR204 have been tech-transferred to SynCore Biotech. DBPR115, DBPR216, and DBPR186 have been tech-transferred to Taivex Biotech. DBPR112 has been tech-transferred to安邦 and DBPR114 to朗齊.
  • 1 anti-EV71 drug candidate (DBPR103) and 2 back-up drug leads/candidates against EV-71 infection.
  • 2 diabetes drug candidate (DBPR108/DBPR211) and several drug leads against diabetes. IBPR had completed the first-in-human Phase I clinical trials for DBPR108 in healthy volunteers in Taiwan in 2015 and tech-transfer process to Genovate Biotech. All phases of the clinical studies had been completed and a new drug application(NDA) was submitted to NMPA, China in early 2023. DBPR211 was tech-transferred to Applied Biopharma LLC, USA.
  • 1 anti-HCV drug candidate (DBPR110) tech-transferred to Microbio.
  • 1 stem cell mobilizing drug candidate (DBPR215), tech-transferred to甲醫.
  • In addition, Dr. Chen has been invited giving more than 180 talks in scientific conferences and training workshops for professional societies, universities, and hospitals in Taiwan and included 4 invited international conference talks. He has mentored 1 Ph.D. and 2 Master graduates, and 15 postdoctoral fellows. Dr. Chen has coauthored more than 165 scientific papers and held the inventorship of more than 30 filed/published/granted patents. He has served as a reviewer for 30 international and domestic journals as well as grant applications for the funding agencies of the government and hospitals.

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

Dr. Chen has established and led a research team responsible for executing the in vivo pharmacological/toxicological evaluations of and for identifying the drug leads and preclinical development drug candidates discovered in the Institute of Biotechnology and Pharmaceutical Research of the NHRI. Dr. Chen has devoted himself to the new drug discovery and development activities in Taiwan for more than 21 years. A number of drug leads and 13 developmental drug candidates against cancer, diabetic, and infectious have been identified with promising pharmacological activities and acceptable toxicological profiles in animals.

Professional and team efforts from Dr. Chen and his group have jointly  contributed to the discoveries and developments of the followings:

a) 8 anticancer drug candidates (intravenously active DBPR104/DBPR114/DBPR115/DBPR807/DBPR117, and orally active DBPR204/DBPR112/DBPR216), of which DBPR104 and DBPR204 have been tech-transferred to SynCore Biotech. DBPR115 and DBPR216 have been tech-transferred to Taivex Biotech.

b) 1 anti-EV71 drug candidate (DBPR103) and 2 back-up drug leads/candidates against EV-71 infection.

c) 2 diabetes drug candidate (DBPR108/DBPR211) and several drug leads against diabetes. DBPR108 has completed Phase I clinical trials in healthy volunteers in Taiwan in 2015. DBPR108 has been tech-transferred to Genovate Biotech and a Phase III clinical study is now ongoing in China.  DBPR211 is in negotiation with a company for licensing terms.

d) 1 anti-HCV drug candidate (DBPR110) tech-transferred to Microbio and now in preparation for clinical study in China.

e)1 stem cell mobilizing drug candidate (DBPR215), which is in progress for negotiation a tech-transfer.

In addition, Dr. Chen has been invited and thus far gave more than 120 talks in scientific conferences and training workshops for professional societies, universities, hospitals and government agencies in Taiwan and 3 invited international symposium seminars. He has mentored 1 Ph.D. and 2 Master graduates, and 15 postdoctoral fellows. Dr. Chen has authored more than 139 scientific papers and held the inventorship of 27 patents published/granted and a few others pending. He has served as an advisory editorial board member and reviewer for 30 international and domestic journals as well as grant applications of government and private hospital funds.

HONORS/AWARDS

  • Co-Recipient, 國家新創獎 (DBPR22998), 2023
  • Co-Recipient, 國家新創獎 (DBPR112), 2022
  • Recipient, 傑出貢獻獎, 中華實驗動物學會 (The Chinese-Taipei Society of Laboratory Animal Sciences), 2020
  • Recipient, Outstanding Alummi, College of Pharmacy, China Medical University, 2018, Taiwan
  • Co-Recipient, Taipei Biotech Award-Gold Medal for Technology Transfer, 2017, Taiwan
  • Co-Recipient, 26th Wang Ming-Ning Memorial Award in Pharmacy, 2016, Taiwan
  • Co-Recipient, “Technology Achievement Award ” by the Ministry of Economic Affairs, 2016, Taiwan
  • Co-Recipient, Taipei Biotech Award-Silver Medal for Technology Transfer, 2016, Taiwan
  • Co-Recipient, Taipei Biotech Award-Gold Medal for Technology Transfer, 2015, Taiwan
  • Co-Recipient, TienTe Lee Excellent Medicine Technology Award, 2014, Taiwan
  • Recipient, Jack L. Beal Post-baccalaureate Alummi Award, 2013, USA
  • Recipient, American Heart Association Fellowship Grant, 1999-2001, USA

PUBLICATIONS (from 2011)

  1. Yao, C.H, Song, S., Chen, C.-T., Hung, M.-S., Chang, C.-C., Liu, Y.-W., Yuan, M.-C., Hsieh, C.-J., Huang, C.-Y., Wang, M.-H., Hsieh, T.-C., Wu, S.-H., Hsiao, W.-C., Chu, K.-F., Tsai, C.-H., Chao, Y.-S., and Lee, J.-C. Discovery of Novel N-β-D-Xylosyl Indole Derivatives as Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Management of Hyperglycemia in Diabetes. J Med Chem. 54(1):166-78, 2011.
  2. Hu, C-B**, Lin, H-L**, Chen, C-P,**, Yeh, T-K, Song, J-S, Chang, C-Y, Chuu, J-J, Tung, F-F, Ho, P-Y, Wang, M-H, Tuan, T-F, Chang, K-Y, Huang, C-L, Li, W-T, Hwang, D-R, Chern, J-H, Hwang, L-L, Chang, J-Y, Chao, Y-S, and Chen, C-T*. BPR0C261 is a novel orally active antitumor agent with antimitotic and antiangiogenic activitie Cancer Sci. 102:(1)182-91, 2011. Jan (SCI) (Sep 10. doi: 10.1111/j.1349-7006.2010.01744.x. [Epub ahead of print])
  3. Yu, C.-P, Wu, P-P; Hou, Y-C, Lin, S-P, Tsai, S-Y; Chen, C-T, Chao, P-D. Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. J Agricultural Food Chem., 59(9):4644-8. April 5, 2011 [Epub ahead of print]
  4. Fung CP, Chang FY, Lin JC, Ho DM, Chen CT, Chen JH, Yeh KM, Chen TL, Lin YT, Siu LK. Immune response and pathophysiological features of Klebsiella pneumoniae liver abscesses in an animal model. Lab Invest. 91(7):1029-39, 2011. doi: 10.1038/labinvest.2011.52. 2011 Apr 4. [Epub ahead of print]
  5. Lin WH, Hsieh SY, Yen SC, Chen CT, Yeh TK, Hsu T, Lu CT, Chen CP, Chen CW, Chou LH, Huang YL, Cheng AH, Chang YI, Tseng YJ, Yen KR, Chao YS, Hsu JT, Jiaang WT. Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). Bioorg Med Chem. 2011 Jul 15;19(14):4173-82. Epub 2011 Jun 13.
  6. Sonaje K**, Lin KJ**, Tseng MT, Wey SP, Su FY, Chuang EY, Hsu CW, Chen C-T*, Sung HW*. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials 32:8712-8721, 2011.
  7. Huang, T.H., Chiu, S.-J., Chiang, P.-H., Chiou, S.-H., Li, W.-T., Chen, C-T, Chang, C.A., Chen, J.C., Lee, Y.-J.* Anti-proliferative effects of N-heterocyclic indolyl glyoxylamides derivatives on human lung cancer cells. Anticancer Res 31(10):3407-15, 2011.
  8. Li, W.T., Hwang, D.R., Song, J.S., Chen, C.P., Chen, T.W., Lin, C.H., Chuu, J.J., Lien, T.W., Hsu, T.A., Huang, C.L., Tseng, H.Y., Lin, C.C., Lin, H.L., Chang, C.M., Chao, Y.S., Chen, C.-T.* Synthesis and Biological Evaluation of 2-Amino-1-thiazolyl Imidazoles as Orally Active Anticancer Agents. Investigational New Drugs 30:164-175, 2012.
  9. Wu, CH, Chang, CP, Song, JS, Jan, JJ, Chou, MC, Wu, SH, Yeh, KC, Wong, YC, Hsieh, CJ, Chen, C–T, Kao, TT, Wu, SY, Yeh, CF, Tseng, CT, Chao, YS, Shia, KS. Discovery of Novel Stem Cell Mobilizers That Target the CXCR4 Receptor. ChemMedChem. 7(2):209-212, 2012. doi: 10.1002/cmdc.201100525.
  10. Lin, W-H**, Jiaang, W-T**, Chen, C-W, Yen, K-R, Hsieh, S-Y, Yen, S-C, Chen, C-P, Chang, K-Y, Chang, CY, Chang, T-Y, Huang, Y-L, Yeh, T.-K., Chao, Y-S, Chen, C-T*, Hsu, J.-A.* BPR1J-097, a novel FLT3 kinase inhibitor, Exerts Potent Inhibitory Activity against AML. Br J Cancer 106(3):475-81, 2012. doi: 10.1038/bjc.2011.564.
  11. Tseng, H-H, Chuah, Q-Y, Yang, P-M, Chen, C-T, Chao, J-C, Lin, M-D, Chiu, S-J. Securin enhances the anti-cancer effects of 6-methoxy-3-(3’,4’,5’-trimethoxy-benzoyl)-1H-indole (BPR0L075) in human colorectal cancer cells. PLoS One 7(4): e36006, 2012. doi:10.1371/journal.pone.0036006
  12. Yang, Y-L, Wang, C-W, Leaw, SN, Chang T-P, Wang I-C, Chen, C-G, Fan, J-C, Tseng, K-Y, Huang S-H, Chen C-Y, Hsiao, T-Y, Hsiung, CA, Chen, C-T, Hsiao, C-D and Lo, H-J. R432 is a key residue for the multiple functions of Ndt80p in Candida albicans. Cell and Mol Life Sci 69(6):1011-23, 2012. Oct 16, 2011 [Epub ahead of print]
  13. Hsu, Li-Wen, Lee, Pei-Ling, Chen, C.-T, Mi, Mi, Fwu-Long, Juang, Jyuhn-Huarng, Hwang, Shiaw-Min, Ho, Yi-Cheng*, Sung, Hsing-Wen*. Elucidating the signalingmechanism of an epithelial tight-junctionopeninginduced by chitosan. Biomaterials 33(26):6254-63, 2012. Jun 6. [Epub ahead of print]
  14. Hsu, John T.-A., Yeh, Teng-Kuang, Yen, Shih-Chieh, Chen, C.-T., Hsieh, Shu-Yi, Hsu, Tsu, Lu, Cheng-Tai, Chen, Chun-Hwa, Chou, Ling-Hui, Chu, Ching-Hui, Chang, Yun-I, Tseng, Ya-Ju, Yen, Kuei-Rong, Chao, Yu-Sheng, Lin, Wen-Hsing, Jiaang, Weir-Torn. 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3) Bioorg Med Chem Lett, 22(14):4654-9, 2012. July. doi: 10.1016/j.bmcl.2012.05.116. Epub 2012 Jun 7.
  15. Tuan, T-F, Chung, CT, Tsou, H-H, Chen, F-W, Lin, H-L, Lai, YK, Lee, W-S, Chao, YS, Hwang, L-L*, Chen, C-T*. Putative tumor metastasis-associated genes in human gastric c Int J Oncol, 41:1068-1084, 2012. May 31. doi: 10.3892/ijo.2012.1502. [Epub ahead of print]
  16. Lin, KT, Wang, YW, Chen, C-T, Ho, C.M., Su, W.H., Jou, Y-S. HDAC inhibitors augmented cell migration and metastasis through activation of PKCs led to identification of novel low toxic modalities for combination cancer therapy. Clin Cancer Res, July 18, 2012; DOI:10.1158/1078-0432. [Epub ahead of print]
  17. Chun-Hsu Yao, Jen-Shin Song, Chiung-Tong Chen, Teng-Kuang Yeh, Tsung-Chih Hsieh, Szu-Huei Wu, Chung-Yu Huang, Yu-Lin Huang, Min-Hsien Wang, Yu-Wei Liu, Chi-Hui Tsai, Chidambaram Ramesh Kumar, Jinq-Chyi Lee. Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors. Eur J Med Chem, 55:32-8, 2012. September. doi: 10.1016/j.ejmech.2012.06.053. Epub 2012 Jul 4.
  18. Chu, C, Huang, X, Chen, C-T, Zhao, Y, Luo, JJ, Gray, BD, Pak, KY, Dun, NJ. In vivo imaging of brain infarct with a novel fluorescent probe PSVue®794 in a rat middle cerebral artery occlusion-reperfusion model. Molecular Imaging, 12(1):8-16, 2013.
  19. Li-Wen Hsua, Yi-Cheng Ho, Er-Yuan Chuang, Chiung-Tong Chen, Jyuhn-Huarng Juang, Fang-Yi Su, Shiaw-Min Hwang, Hsing-Wen Sung. Effects of pH on molecular mechanisms of chitosan-integrin interactions and resulting tight-junction disruptions. Biomaterials 34:784-793, 2013.
  20. Ho, Pai-Jiun, Yen, Men-Luh, Tang, Bo-Chung, Chen, C.-T., Yen, B. Linju. H2O2 accumulation mediate differentiation capacity alteration but not proliferative decline in senescent human

fetal mesenchymal stem cells. Antioxidants Redox Signaling, 18(15):1895-905, 2013. May. doi: 10.1089/ars.2012.4692. Epub 2012 Dec 20.

  1. Jiun-Ming Wu, Chiung-Tong Chen, Mohane Selvaraj Coumar, Wen-Hsin Lin, Zi-Jie Chen, John T.-A Hsu, Yi-Hui Peng, Hui-Yi Shiao, Wen-Hsing Lin, Chang-Ying Chu, Jian-Sung Wu, Chih-Tsung Lin, Ching-Ping Chen, Ching-Cheng Hsueh, Kai-Yen Chang, Li-Pin Kao, Chi-Ying F. Huang, Yu-Sheng Chao, Su-Ying Wu, Hsing-Pang Hsieh and Ya-Hui Chi. Novel Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules. Proc Nat Acad Sci, USA, 110(19):E1779-87, May. doi/10.1073/pnas.1220523110.
  2. Lin WH, Hsu JT, Hsieh SY, Chiung-Tong Chen, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). Bioorg Med Chem, 21(11):2856-2867, 2013. June. pii: S0968-0896(13)00317-9. doi: 10.1016/j.bmc.2013.03.083. [Epub ahead of print].
  3. Er-Yuan Chuang, Kun-Ju Lin, Fang-Yi Su, Fwu-Long Mi, Barnali Maiti, Chiung-Tong Chen, Shiaw-Pyng Wey, Tzu-Chen Yen, Jyuhn-Huarng Juang, Hsing-Wen Sung. Noninvasive imaging oral absorption of insulin and its stimulated glucose utilization in controlling postprandial hyperglycemia during OGTT in diabetic rats. J Controll Rel, 2013 May. pii: S0168-3659(13)00253-8. doi: 10.1016/j.jconrel.2013.05.006. [Epub ahead of print]
  4. Hui-Ching Ko,Ting-Yin Hsiao, Chiung-Tong Chen, Yun-Liang Yang. Candida albicans ENO1 null mutants exhibit altered drug susceptibility, hyphal formation, and virulence J Microbiol, 51(3):345-351, 2013. June.
  5. Hui-Yi Shiao, Mohane Selvaraj Coumar, Chun-Wei Chang, Yi-Yu Ke, Chang-Ying Chu, Hsu-Yi Sun, Chun-Hwa Chen, Wen-Hsing Lin, Ka-Shu Fung, Po-Chu Kuo, Chin-Ting Huang, Kai-Yen Chang, Cheng-Tai Lu, John T. A. Hsu, Chiung-Tong Chen, Weir-Torn Jiaang, Yu-Sheng Chao, Hsing-Pang Hsieh. Optimization of ligand and lipophilic efficiency to identify in vivo active furano-pyrimidine aurora kinase inhibitor. J Med Chem. 56(13):5247-60, 2013 Jun 28. [Epub ahead of print]
  6. Haw-Wen Chen, Hsien-Tsung Yao, Pei-Fen Liu, Chien-Chun Li, Chiung-Tong Chen, Cheng-Tzu Liu, Jia-Rong Chiang, and Chong-Kuei Lii. Andrographis paniculata Extract and Andrographolide Modulate the Hepatic Drug Metabolism System and Plasma Tolbutamide Concentrations in Rats. Evid Based Complement Alternat Med, Article ID 982689, 2013.
  7. Chuang EY, Nguyen GTH, Su FY, Lin KJ, Chen CT, Mi FL, Yen TC, Juang JH, Sung HW. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT. Biomaterials, 34(32):7994-8001, 2013. October.
  8. Li, Wen-Tai, Yeh, Teng-Kuang, Song, Jen-Shin, Chen, Tung-Wei, Lin, Chi-Hung, Chen, Ching-Ping, Huang, Chen-Lung, Shen, Chien-Chang, Lin, Heng-Liang, Chao, Yu-Sheng, Chen, C.-T.* BPR0C305, an orally active microtubule-disrupting anticancer agent. Anti-Cancer Drugs, 24(10):1047-57, 2013. November, doi: 10.1097/CAD.0000000000000014.
  9. Wen-Hsing Lin, Teng-Kuang Yeh, Weir-Torn Jiaang, Kuei-Jung Yen, Chun-Hwa Chen, Chin-Ting Huang, Shih-Chieh Yen, Shu-Yi Hsieh, Ling-Hui Chou, Ching-Ping Chen, Chun-Hsien Chiu, Li-Chun Kao, Yu-Sheng Chao, Chiung-Tong Chen*, John T.-A. Hsu*. Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, Vorinostat , in AML cancer. PLoS One, (1), e83160, 2014. January
  10. Su FY, Chuang EY, Lin PY, Chou YC, Chen C–T, Mi FL, Wey SP, Yen TC, Lin KJ, Sung HW. Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles. Biomaterials, 35(11):3641-9, 2014. April doi: 10.1016/j.biomaterials.2014.01.020. Epub 2014 Jan 27.
  11. Jyuhn-Huarng Juang, Chien-Hung Kuo, Ying-Hsiu Liu, Han-Yin Chang and Chiung-Tong Chen. Effects of Dipeptidyl Peptidase 4 Inhibition with MK-0431 on Syngeneic Mouse Islet Transplantation. Intl J Endocrinol, Article ID 795283, 2014. http://dx.doi.org/10.1155/2014/795283.
  12. Lee CH, Chang JS, Syu SH, Wong TS, Chan JY, Tang YC, Yang ZP, Yang WC, Chen CT, Lu SC, Tang PH, Yang TC, Chu PY, Hsiao JR, Liu KJ. IL-1beta promotes malignant transformation and tumor aggressiveness in oral cancer. J Cell Physiol 2015 230(4):875-884.
  13. Wu CH, Song JS, Chang KH, Jan JJ, Chen CT, Chou MC, Yeh KC, Wong YC, Tseng CT, Wu SH, Yeh CF, Huang CY, Wang MH, Sadani AA, Chang CP, Cheng CY, Tsou LK, Shia KS. Stem Cell Mobilizers Targeting Chemokine Receptor CXCR4: Renoprotective Application in Acute Kidney Injury. J Med Chem. 2015 Mar 12;58(5):2315-25. doi: 10.1021/jm501769r.
  14. Chen CT, Hsu JT, Lin WH, Lu CT, Yen SC, Hsu T, Huang YL, Song JS, Chen CH, Chou LH, Yen KJ, Chen CP, Kuo PC, Huang CL, Liu HE, Chao YS, Yeh TK, Jiaang WT. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations. Eur J Med Chem. 2015 May 9;100:151-161. doi: 10.1016/j.ejmech.2015.05.008. [Epub ahead of print]
  15. Chuang EY, Lin KJ, Lin PY, Chen HL, Wey SP, Mi FL, Hsiao HC, Chen CT*, Sung HW*. Self-assembling bubble carriers for oral protein delivery, Biomaterials Sep;64:115-24. doi: 10.1016/j.biomaterials.2015.06.035. Epub 2015 Jun 20.
  16. Chen HH, Wang TC, Lee YC, Shen PT, Chang JY, Yeh TK, Huang CH, Chang HH, Cheng SY, Lin CY, Shih C, Chen CT, Liu WM, Chen CH, Kuo CC. Novel Nrf2/ARE Activator, trans-Coniferylaldehyde, Induces a HO-1-Mediated Defense Mechanism through a Dual p38α/MAPKAPK-2 and PK-N3 Signaling Pathway. Chem Res Toxicol. 2015 Aug 24. [Epub ahead of print]
  17. Chu KF, Yao CH, Song JS, Chen CT, Yeh TK, Hsieh TC, Huang CY, Wang MH, Wu SH, Chang WE, Chao YS, Lee JC. N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors. Bioorg Med Chem. 2016 May 15;24(10):2242-50. doi: 10.1016/j.bmc.2016.03.058. Epub 2016 Mar 30.
  18. Li-TzongChen**, Chiung-Tong Chen**, Weir-Torn Jiaang**, Tsai-Yun Chen, Joseph H. Butterfield, Neng-Yao Shih, John Tsu-An Hsu, Hui-You Lin, Sheng-Fung Lin and Hui-Jen Tsai BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT driven myeloid leukemia. Molecular Cancer Therapeutics. 2016 Oct;15(10):2323-2333.
  19. Kou-Jen Wu, Seong-Jin Yu, Kak-Shan Shia, Chien-Huang Wu, Jen-Shin Song, Hsuan-Hao Kuan, Kai-Chia Yeh, Chiung-Tong Chen, Eunkyune Bae, and Yun Wang. A novel CXCR4 antagonist CX549 induces neuroprotection in stroke brain. Cell Transplant. 2016 Oct 27. doi:10.3727/096368916X693563.
  20. Hsu YC, Coumar MS, Wang WC, Shiao HY, Ke YY, Lin WH, Kuo CC, Chang CW, Kuo FM, Chen PY, Wang SY, Li AS, Chen CH, Kuo PC, Chen CP, Wu MH, Huang CL, Yen KJ, Chang YI, Hsu JT, Chen CT, Yeh TK, Song JS, Shih C, Hsieh HP. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. Oncotarget. 2016 Nov 15. doi:10.18632/oncotarget.13369.
  21. Chao PK, Ueng SH, Ou LC, Yeh TK, Chang WT, Chang HF, Chen SC, Tao PL, Law PY, Loh HH, Cheng MF, Chuang JY, Chen CT, Shih C, Yeh SH. 1-(2,4-Dibromophenyl)-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one: A Novel Opioid Receptor Agonist with Less Accompanying Gastrointestinal Dysfunction than Morphine. Anesthesiology. 2017 May;126(5):952-966. doi: 10.1097/ALN.0000000000001568.
  22. Yeh TK, Kuo CC, Lee YZ, Ke YY, Chu KF, Hsu HY, Chang HY, Liu YW, Song JS, Yang CW, Lin LM, Sun M, Wu SH, Kuo PC, Shih C, Chen CT, Tsou LK, Lee SJ. Design, synthesis, and evaluation of thiazolidine-2-4-dione derivatives as a novel class of glutaminase inhibitors. J Med Chem. 2017 Jun 13. doi: 10.1021/acs.jmedchem.7b00282. [Epub ahead of print]
  23. Liu YW, Shia KS, Wu CH, Liu KL, Yeh YC, Lo CF, Chen CT, Chen YY, Yeh TK, Chen WH, Jan JJ, Huang YC, Huang CL, Fang MY, Gray BD, Pak KY, Hsu TA, Huang KH, Tsou LK. Targeting Tumor Associated Phosphatidylserine with New Zinc Dipicolylamine-Based Drug Conjugates. Bioconjug Chem. 2017 Jun 19. doi: 10.1021/acs.bioconjchem.7b00225. [Epub ahead of print]
  24. In-Yu Lin, Min-Hsiung Pan, Ching-Shu Lai, Ting Ting Lin, Chiung-Tong Chen, Tao-Sheng Chung, Chien-Lung Chen, Chen-Huan Lin, Wu-Chang Chuang, Ming-Chung Lee, Ching-Che Lin, Nianhan Ma. CCM111, the water extract of Antrodia cinnamomea, regulates immune-related activity through STAT3 and NF-kB pathways. Sci Rep. 2017 Jul 7;7(1):4862. doi: 10.1038/s41598-017-05072-y.
  25. Yuan, MC; Yeh, TK; Chen, CT; Song, JS; Huang, YC; Hsieh, TC; Huang, CY; Huang, YL; Wang, MH; Wu, SH; Yao, CH; Chao, YS; Lee, JC. Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2. Eur J Med Chem. 2018 Jan 1; 143: 611-620.
  26. Lee, WS; Lu, YC; Kuo, CT; Chen, CT; Tang, PH. Effects of female sex hormones on folic acid-induced anti-angiogenesis. Acta Physiologica. 2018 Apr;222(4):e13001. doi: 10.1111/apha.13001. Epub 2017 Dec 15.
  27. Yeh HW, Hsu EC, Lee SS, Lang YD, Lin YC, Chang CY, Lee SY, Gu DL, Shih JH, Ho CM, Chen CF, Chen CT, Tu PH, Cheng CF, Chen RH, Yang RB, Jou YS. PSPC1 mediates TGF-β1 autocrine signalling and Smad2/3 target switching to promote EMT, stemness and metastasis. Nat Cell Biol. 2018 Apr;20(4):479-491. doi: 10.1038/s41556-018-0062-y. Epub 2018 Mar 28.
  28. Chuang, Er-Yuan; Lin, Kun-Ju; Huang, Tring-Yo; Chen, Hsin-Lung; Miao, Yang-Bao; Lin, Po-Yen; Chen, Chiung-Tong; Juang, Jyuhn-Huarng; Sung, Hsing-Wen. An Intestinal “Transformers”-Like Nanocarrier System for Enhancing the Oral Bioavailability of Poorly Water-Soluble Drugs. ACS Nano, 2018 Jul 24;12(7):6389-6397. doi: 10.1021/acsnano.8b00470. Epub 2018 Jun 6.
  29. Tsai HJ, Jiaang WT, Shih NY, Fletcher JA, Lin MJ, Yang MY, Chen CT, Hsu TJ, Wu CC, Lin HY, Chen LT. BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor. Cancer Sci. 2018 Nov;109(11):3591-3601. doi: 10.1111/cas.13773. Epub 2018 Sep 21.
  30. Lai YJ, Yu WN, Kuo SC, Ho CT, Hung CM, Way TD, Chen CT. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma. J Cell Physiol. 2018 Oct 20. doi: 10.1002/jcp.27589.
  31. Chu KF, Song JS, Chen CT, Yeh TK, Hsieh TC, Huang CY, Wang MH, Wu SH, Yao CH, Chao YS, Lee JC. Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors. Bioorg Chem. 2018 Nov 7;83:520-525. doi: 10.1016/j.bioorg.2018.11.006.
  32. Lin YJ, Mi FL, Lin PY, Miao YB, Huang T, Chen KH, Chen CT, Chang Y, Sung HW. Strategies for improving diabetic therapy via alternative administration routes that involve stimuli-responsive insulin-delivering systems. Adv Drug Deliv Rev. 2018 Dec 6. pii: S0169-409X(18)30303-X. doi: 10.1016/j.addr.2018.12.001.
  33. In-Yu Lin, Yi-Shiou Chiou, Li-Ching Wu, Chen-Yu Tsai, Chiung-Tong Chen, Wu-Chang Chuang, Ming-Chung Lee, Ching-Che Lin, Ting-Ting Lin, Ssu-Ching Chen, Min-Hsiung Pan, Nianhan Ma. CCM111 prevents hepatic fibrosis via cooperative inhibition of TGF-β, Wnt and STAT3 signaling pathways. J Food Drug Anal. 2019 Jan;27:184-194. DOI: https://doi.org/10.1016/j.jfda.2018.09.008.
  34. Teng-Kuang Yeh, Iou-Jiun Kang, Tsu-An Hsu, Yen-Chun Lee, Chung-Chi Lee, Sheng-Ju Hsu, Ya-Wen Tian, Hui-Yun Yang, Chiung-Tong Chen, Yu-Sheng Chao, Andrew Yueh, Jyh-Haur Chern. A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus. Eur J Med Chem. 167:245-268, 2019. org/10.1016/j.ejmech.2019.02.016.
  35. Shu-Yu Lin, Yu-Hsien Kuo, Ya-Wen Tien, Yi-Yu Ke, Wan-Ting Chang, Hsiao-Fu Chang, Li-Chin Ou, Ping-Yee Law, Jing-Hua Xi, Pao-Luh Tao, Horace H. Loh, Yu-Sheng Chao, Chuan Shih, Chiung-Tong Chen, Shiu-Hwa Yeh, Shau-Hua Ueng. The in vivo antinociceptive and μ-opioid receptor activating effects of the combination of N-phenyl-2′,4′-dimethyl-4,5′-bi-1,3-thiazol-2-amines and naloxone. Eur J Med Chem. 167:312-323, 2019. doi.org/10.1016/j.ejmech.2019.01.063.
  36. Tian JN, Wu RH, Chen SL, Chen CT, Yueh A. Mutagenesis of the dengue virus NS4A protein reveals a novel cytosolic N-terminal domain responsible for virus-induced cytopathic effects and intramolecular interactions within the N-terminus of NS4A. J Gen Virol. 2019 Mar;100(3):457-470. doi: 10.1099/jgv.0.001227. Epub 2019 Feb 1
  37. Po‐Yen Lin, Kuan‐Hung Chen, Yang‐Bao Miao, Kun‐Ju Lin, Chiung‐Tong Chen, Chun‐Nan Yeh, Yen Chang, Hsing-Wen Sung. Phase-Changeable Nanoemulsions for Oral Delivery of a Therapeutic Peptide: Toward Targeting the Pancreas for Antidiabetic Treatments Using Lymphatic Transport. Adv Functional Materials, 2019 Feb 08;29(13): 1809015,org/10.1002/adfm.201809015.
  38. Wu, Tsung-Sheng ; Lin, Wen-Hsing; Tsai, Hui-Jen ; Hsueh, Ching-Cheng ; Hsu, Tsu; Wang, Pei-Chen; Lin, Hui-You ; Peng, Yi-Hui; Lu, Cheng-Tai ; Lee, Lung-Chun ; Tu, Chih-Hsiang; Kung, Fang-Chun ; Shiao, Hui-Yi; Yeh, Teng-Kuang; Song, Jen-Shin; Chang, Jia-Yu; Su, Yu-Chieh; Chen, Li-Tzong; Chen, Chiung-Tong; Jiaang, Weir-Torn; Wu, Suying. Discovery of conformational control inhibitors switching off the activated c-KIT and targeting a broad range of clinically relevant c-KIT mutants. Med. Chem, 2019 Apr 25;62(8):3940-3957. doi: 10.1021/acs.jmedchem.8b01845. Epub 2019 Apr 10.
  39. Lin LC, Lee LC, Huang C, Chen CT, Song JS, Shiao YJ, Liu HK. Effects of boschnaloside from Boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1. 2019 May 6;62:152946. doi: 10.1016/j.phymed.2019.152946. [Epub ahead of print]
  40. Liu YW, Chen YY, Hsu CY, Chiu TY, Liu KL, Lo CF, Fang MY, Huang YC, Yeh TK, Pak KY, Gray BD, Hsu TA, Huang KH, Shih C, Shia KS, Chen CT*, Tsou LK*. Linker Optimization and Therapeutic Evaluation of Phosphatidylserine-Targeting Zinc Dipicolylamine-based Drug Conjugates. J Med Chem. 2019 Jul 11;62(13):6047-6062. doi: 10.1021/acs.jmedchem.9b00173. Epub 2019 Jun 20.
  41. Yu WN, Lai YJ, Ma JW, Ho CT, Hung SW, Chen YH, Chen CT, Kao JY, Way TD. Citronellol Induces Necroptosis of Human Lung Cancer Cells via TNF-α Pathway and Reactive Oxygen Species Accumulation. In Vivo. 2019 Jul-Aug;33(4):1193-1201. doi: 10.21873/invivo.11590.
  42. Tian JN, Yang CC, Chuang CK, Tsai MH, Wu RH, Chen CT, Yueh A. A Dengue Virus Type 2 (DENV-2) NS4B-Interacting Host Factor, SERP1, Reduces DENV-2 Production by Suppressing Viral RNA Replication. Viruses. 2019 Aug 27;11(9):787. doi: 10.3390/v11090787.
  43. Lin SY, Chang Hsu Y, Peng YH, Ke YY, Lin WH, Sun HY, Shiao HY, Kuo FM, Chen PY, Lien TW, Chen CH, Chu CY, Wang SY, Yeh KC, Chen CP, Hsu TA, Wu SY, Yeh TK, Chen CT, Hsieh HP. Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. J Med Chem. 2019 Nov 27;62(22):10108-10123. doi: 10.1021/acs.jmedchem.9b00722. Epub 2019 Nov 15.
  44. Yang CC, Hu HS, Lin HM, Wu PS, Wu RH, Tian JN, Wu SH, Tsou LK, Song JS, Chen HW, Chern JH, Chen CT, Yueh A. A novel flavivirus entry inhibitor, BP34610, discovered through high-throughput screening with dengue reporter viruses. Antiviral Res. 2019 Dec;172:104636. doi: 10.1016/j.antiviral.2019.104636. Epub 2019 Oct 23.
  45. Wen-Hsing Lin, Su-Ying Wu, Teng-Kuang Yeh, Chiung-Tong Chen, Jen-Shin Song, Hui-Yi Shiao, Ching-Chuan Kuo, Tsu Hsu, Cheng-Tai Lu, Pei-Chen Wang, Tsung-Sheng Wu, Yi-Hui Peng, Hui-You Lin, Ching-Ping Chen, Ya-Ling Weng, Fang-Chun Kung, Mine-Hsine Wu, Yu-Chieh Su, Kuo-Wei Huang, Ling-Hui Chou, Ching-Cheng Hsueh, Kuei-Jung Yen, Po-Chu Kuo, Chen-Lung Huang, Li-Tzong Chen, Chuan Shih, Hui-Jen Tsai,and Weir-Torn Jiaang. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia Med. Chem. 2019, 62, 11135−11150.
  46. Yen-Ju Chen, Chin-Yi Tsai, Ying-Min Cheng, Su-Wen Nieh, Teng-Kuang Yeh Ching-Ping Chen, Min-Hsien Wang, Ling-Hui Chou, Tai-Yu Chiu, Li Liu, Chien Ho*, Chiung-Tong Chen*, and Tsang-Wu Liu*. Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System. Sci Rep. 2020; 10: 2020 Feb 18. doi: 10.1038/s41598-020-59813-7
  47. Yi-Yu Ke*, Tzu-Ting Peng, Teng-Kuang Yeh, Wen-Zheng Huang, Shao-En Chang, Szu-Huei Wu, Hui-Chen Hung, Tsu-An Hsu, Shiow-Ju Lee, Jeng-Shin Song, Wen-Hsing Lin, Tung-Jung Chiang, Jiunn-Horng Lin, Huey-Kang Sytwu, Chiung-Tong Chen*. Artificial intelligence approach fighting COVID-19 with repurposing drugs. Biomed J. 2020 May 15. doi: 10.1016/j.bj.2020.05.001. Online ahead of print.
  48. Cheng-Wei Yang, Tzu-Ting Peng, Hsing-Yu Hsu, Yue-Zhi Lee, Szu-Huei Wu, WenHsing Lin, Yi-Yu Ke, Tsu-An Hsu, Teng-Kuang Yeh, Wen-Zheng Huang, Jiunn-Horng Lin, Huey-Kang Sytwu, Chiung-Tong Chen*, Shiow-Ju Lee*. Repurposing old drugs as antiviral agents for coronaviruses. Biomed J. 2020 May, org/10.1016/j.bj.2020.05.003
  49. Kuan-Hung Chen, Yang-Bao Miao, Chun-Yu Shang, Tring-Yo Huang, Yu-Tzu Yu, Chun-Nan Yeh, Hsiang-Lin Song, Chiung-Tong Chen, Fwu-Long Mi, Kun-Ju Lin, and Hsing-Wen Sung. A Bubble Bursting-Mediated Oral Drug Delivery System That Enables Concurrent Delivery of Lipophilic and Hydrophilic Chemotherapeutics for Treating Pancreatic Cancer. Biomaterials. Available online 3 June 2020, 120157, 1016/j.biomaterials.2020.120157
  50. Hui-chen Hung, Yi-Yu Ke, Sheng-Yu Huang, Peng-Nien Huang, Yu-An Kung, Teng-Yuan Chang, Kuei-Jung Yen, Tzu-Ting Peng, Shao-En Chang, Chin-Ting Huang, Ya-Ru Tsai, Szu-Huei Wu, Shiow-Ju Lee, Jiunn-Horng Lin, Bing-Sin Liu, Wang-Chou Sung, Shin-Ru Shih*, Chiung-Tong Chen*, and John Hsu*. Discovery of M Protease inhibitors encoded by SARS-CoV-2. Antimicrobial Agents and Chemotherapy. 2020 Jul 15:AAC.00872-20. doi: 10.1128/AAC.00872-20. Online ahead of print. 2020 Aug 20;64(9):e00872-20. Print 2020 Aug 20
  51. Cheng-Ta Chung, Kai-Chia Yeh, Chia-Huei Lee, Yun-Yu Chen, Pai-Jiun Ho, Kai-Yen Chang, Chieh-Hsin Chen, Yiu-Kay Lai*, Chiung-Tong Chen*. Molecular Profiling of Afatinib-Resistant Non-Small Cell Lung Cancer Cells in vivo Derived from Mice. Pharmacol Res. 161: 105183, doi: 10.1016/j.phrs.2020.105183, 2020.
  52. Yun-Yu Chen#, Chen-Fu Lo#, Tai-Yu Chiu#, Chia-Yu Hsu#, Teng-Kuang Yeh#, Ching-Ping Chen, Chen-Lung Huang, Chung-Yu Huang, Min-Hsien Wang, Yu-Chen Huang, Hsuan-Hui Ho, Yu-Sheng Chao, Joe C. Shih, Lun K. Tsou* and Chiung-Tong Chen*. BPRDP056, a Novel Small Molecule Drug Conjugate Specifically Targeting Phosphatidylserine for Cancer Therapy. Translational Oncology 14 (2021) 100897, Available online 15 October 2020. http://dx.doi.org/10.1016/j.tranon.2020.100897.
  53. Zheng-Sheng Lai, Teng-Kuang Yeh, Yu-Chi Chou, Tsu Hsu, Cheng-Tai Lu, Fang-Chun Kung, Ming-Yen Hsieh, Chun-Hung Lin, Chiung-Tong Chen, Che-Kun James Shen, Weir-Torn Jiaang. Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease. J. Med. Chem. 2020, doi: 10.1016/j.ejmech.2020.112938. Available online 16 October 2020, 112938.
  54. Tsou LK, Yeh SH, Ueng SH, Chang CP, Song JS, Wu MH, Chang HF, Chen SR, Shih C, Chen CT, Ke YY. Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery. Sci Rep. 2020 Oct 8;10(1):16771. doi: 10.1038/s41598-020-73681-1.
  55. Jyuhn-Huarng Juang, Chen-Yi Chen, Chen-Wei Kao, Yu-Wen Huang, Tai-Yu Chiu, Chiung-Tong Chen. Implanted islet mass influences the effects of dipeptidyl peptidase-IV inhibitor LAF237 on transplantation outcomes in diabetic mice. Biomedical Journal, Available online 10 October 2020. doi: 10.1016/j.bj.2020.10.002
  56. Cheng-Wei Yang, Yue-Zhi Lee, Hsing-Yu Hsu, Jia-Tsrong Jan, Yi-Ling Lin, Sui-Yuan Chang, Tzu-Ting Peng, Ruey-Bing Yang, Jian-Jong Liang, Chun-Che Liao, Tai-Ling Chao, Yu-Hau Pang, Han-Chieh Kao, Wen-Zheng Huang, Jiunn-Horng Lin, Szu-Huei Wu, Huey-Kang Sytwu, Chiung-Tong Chen, and Shiow-Ju Lee. Inhibition of SARS-CoV-2 by highly potent broad-spectrum anti-coronaviral tylophorine-based derivatives. Frontiers in Pharmacology, 11:Article 606097, 14 December 2020,org/10.3389/fphar.2020.606097.
  57. Chi, Ya-Hui ; Yeh, Teng-Kuang; Ke, YI-YU;  Lin, Wen-Hsing; Tsai , Chia-Hua; Wang, Wan-Ping ; Chen, Yen-Ting ; Su, Yu-Chieh ; Wang , Pei-Chen ;  Chen, Yan-Fu;  Wu, Zhong-Wei; Yeh, Jen-Yu ; Hung, Ming-Chun ;  Wu, Mine-Hsine; Wang,  Jing-Ya; Chen, Ching-Ping ; Song, Jen-Shin; Shih, Chuan ; Chen, Chiung-Tong ; Chang, Chun-Ping. Discovery and Synthesis of a Pyrimidine-based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins”. Med. Chem. 64(11):7312-7330, 2021. doi: 10.1021/acs.jmedchem.0c01806. Epub 2021 May 19.
  58. Yang-Bao Miao, Kuan-Hung Chen, Chiung-Tong Chen, Fwu-Long Mi, Yu-Jung Lin, Yen Chang, Chi-Shiun Chiang, Jui-To Wang, Kun-Ju Lin, Hsing-Wen Sung. A Noninvasive Gut-to-Brain Oral Drug Delivery System for Treating Brain Tumors. Advanced Materials, DOI:10.1002/adma.202100701, 2021.
  59. Kai-Chia Yeh†, Teng-Kuang Yeh†,*, Chung-Yu Huang, Chih-Bo Hu, Min-Hsien Wang, Yu-Wen Huang, Ling-Hui Chou, Hsuan-Hui Ho, Jen-Shin Song, Tsu Hsu, Weir-Torn Jiaang, Yu-Sheng Chao and Chiung-Tong Chen*. DBPR108, A Novel Dipeptidyl Peptidase-IV Inhibitor with Antihyperglycemic Activity. Life Sciences, 278:119574, 2021.
  60. Hsing-Yu Hsu, Cheng-Wei Yang, Yue-Zhi Lee, Yi-Ling Lin, Sui-Yuan Chang, Ruey-Bing Yang, Jian-Jong Liang, Tai-Ling Chao, Chun-Che Liao, Han-Chieh Kao, Szu-Huei Wu, Jang-Yang Chang, Huey-Kang Sytwu, Chiung-Tong Chen and Shiow-Ju Lee. Remdesivir and cyclosporine synergistically inhibit the human coronaviruses OC43 and SARS-CoV-2. Frontiers in Pharmacology, 13 August 2021. org/10.3389/fphar.2021.706901.
  61. Mu-Chun Li, Wen-Hsing Lin, Pei-Chen Wang, Yu-Chieh Su, Pei-Yi Chen, Chu-Min Fan, Ching-Ping Chen, Chen-Lung Huang, Chun-Hsien Chiu, Ling Chang, ChiungTong Chen, Teng-Kuang Yeh, Hsing-Pang Hsieh. Design and synthesis of novel orally selective and type II Pan-TRK inhibitors to overcome mutations by property-driven optimization. EJMC in press, 2021. Epub 2021 June 29 2021, 113673.
  62. Kun-Hung Lee, Wan-Ching Yen, Wen-Hsing Lin, Pei-Chen Wang, You-Liang Lai, Yu-Chieh Su, Chun-Yu Chang, Cai-Syuan Wu, Yu-Chen Huang, Chen-Ming Yang, Ling-Hui Chou, Teng-Kuang Yeh, Chiung-Tong Chen, Chuan Shih, and Hsing-Pang Hsieh. Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model. J Med. Chem. 64(19):14477-14497, 2021. DOI: 10.1021/acs.jmedchem.1c01006.
  63. Yang-Bao Miao, Yu-Jung Lin, Kuan-Hung Chen, Po-Kai Luo, Shun-Hao Chuang, Yu-Tzu Yu, Hsien-Meng Tai, Chiung-Tong Chen, Kun-Ju Lin, Hsing-Wen Sung. Engineering Nano- and Microparticles as Oral Delivery Vehicles to Promote Intestinal Lymphatic Drug Transport. Advanced Materials, 01 October 2021. https://doi.org/10.1002/adma.202104139.

PATENTS FILED AND GRANTED

  1. Chiung-Tong Chen, Shu-Jen Chen, Ming-Chu Hsu, Der-Ren Hwang, Wen-Tai Li, Chu-Chung Lin. Indolyl-3-yl-2-oxoacetamide compounds and methods of use thereof. US 6,903,104 B2. Granted for June 7th, 2005 – December 2022.
  2. Chiung-Tong Chen, Wen-Tai Li, Der-Ren Hwang, Chu-Chung Lin. Imidazolamino compounds. US 7,109,227. Granted for Sept. 19th, 2006 – Aug. 26th, 2023.
  3. Chiung-Tong Chen, Jang-Yang Chang. 一種用以抑制癌細胞之醫藥組合物,Taiwan, ROC I228417. Granted for March 1st, 2005 – Sept. 26th, 2022. (Gave up)
  4. Chiung-Tong Chen, Wen-Tai Li, Der-Ren Hwang, Chu-Chung Lin,.Shu-Jen Chen, Ming-Chu Hsu. 吲哚-3-基-2-氧乙醯胺衍生物之新化合物及其醫藥組合物與備製方法, Taiwan, ROC I323658, Granted for April 21, 2010 – December 04, 2022.
  5. Chiung-Tong Chen, Wen-Tai Li, Der-Ren Hwang, Chu-Chung Lin. 咪唑胺化合物, Taiwan, R.O.C. Patent I324596, Granted for May 11, 2010 – August 25, 2023.
  6. Jyh-Haur Chern, Shin-Ru Shih, Chiung-Tong Chen, Chih-Shiang Chang, Chung-Chi Lee, Yen-Chun Lee, Chia-Liang Tai, Imidazolidinone compounds. US 7,129,359 B2. Granted for October 31st, 2006 – September 2nd, 2023.
  7. Jyh-Haur Chern, Shin-Ru Shih, Chiung-Tong Chen, Chih-Shiang Chang, Chung-Chi Lee, Yen-Chun Lee, Chia-Liang Tai. 咪唑啉酮化合物. Taiwan, ROC I281919. Granted for June 1st, 2007 – November 17th, 2024.
  8. Chiung-Tong Chen, Shu-Jen Chen, Ming-Chu Hsu, Der-Ren Hwang, Wen-Tai Li, Chu-Chung Lin. Use of 1H-indol-3-yl-2-oxoacetamide compounds. US 7,396,838 B2. Granted for July 8th, 2008 – February 28th, 2023.
  9. Chiung-Tong Chen, Wen-Tai Li, Der-Ren Hwang, Chu-Chung Lin. Imidazolamino compounds. US 7,462,723 B2. Granted for December 9th, 2008 – August 26th, 2023.
  10. Jyh-Haur Chern, Shin-Ru Shih, Chiung-Tong Chen, Chih-Shiang Chang, Chung-Chi Lee, Yen-Chun Lee, Chia-Liang Tai, Imidazolidinone compounds. US 7,501,445 B2. Granted for March 10th, 2009 – June 13th, 2023.
  11. Chiung-Tong Chen, Wen-Tai Li, Der-Ren Hwang, Chu-Chung Lin. Imidazolamino compounds. US 7,569,596 B2. Granted for August 4th, 2009 – February 17th, 2024.
  12. Chiung-Tong Chen, Shu-Jen Chen, Ming-Chu Hsu, Der-Ren Hwang, Wen-Tai Li, Chu-Chung Lin. Methods of 1H-indol-3-yl-2-oxoacetamide compounds. US 7,662,834 B2. Granted for February 16th, 2010 – December 5th, 2022.
  13. Jyh-Haur Chern, Shin-Ru Shih, Chiung-Tong Chen, Chih-Shiang Chang, Chung-Chi Lee, Yen-Chun Lee, Chia-Liang Tai. 咪唑啉酮化合物, Taiwan, ROC I324594, Granted for May 11, 2010 – November 17, 2024.
  14. Teng-Kuang Yeh, Chiung-Tong Chen, Yu-Sheng Chao. Formulations of indol-3-yl-2-oxoacetamide compounds, US 8,026,271 B2, Granted for September 27, 2011 – May 25, 2029.
  15. Teng-Kuang Yeh, Chiung-Tong Chen, Yu-Sheng Chao. 抗癌口服藥學組成物,Taiwan ROC I384984, Granted for February 11, 2013 – July 8th, 2029.
  16. Teng-Kuang Yeh, Chiung-Tong Chen, Yu-Sheng Chao. 抗癌口服制剂, China ZL 200980126979.4, Granted for June 4th, 2014 – July 10th, 2029.
  17. Teng-Kuang Yeh, Chiung-Tong Chen, Yu-Sheng Chao. Anticancer oral formulation, Japan 特許第5596680號, Granted for August 15th, 2014 – July 10th, 2029.
  18. Teng-Kuang Yeh, Chiung-Tong Chen, Yu-Sheng Chao. Anticancer oral formulation, EP 2310363, Granted for June 5th, 2013 – July 10th, 2029.
  19. Teng-Kuang Yeh, Chiung-Tong Chen, Yu-Sheng Chao. Anticancer oral formulation, Korea, 10-1627382, Granted for June 5th, 2013 – July 10th, 2029.
  20. Tsung-Fan Tuan, Heng-Liang Lin and Chiung-Tong Chen, Genes relating to gastric cancer metastasis. US 60/966,074, filed on August 24th, 2007; US 2009/0111109 A1, published on April 30, 2009. (Gave up)
  21. Tsung-Fan Tuan, Heng-Liang Lin and Chiung-Tong Chen, 與轉移性胃癌相關的基因Taiwan ROC patent, Case # 97132402, August 25th, 2008. (Gave up)
  22. Chiung-Tong Chen, Kak-Shan Shia, Chien-Huang Wu, Lun Kelvin Tsou, Yu-Sheng Chao. Dipicolylamine derivatives and their pharmaceutical uses, US Granted for July 12th, 2016 – May 14th, 2035.
  23. Chiung-Tong Chen, Kak-Shan Shia, Chien-Huang Wu, Lun Kelvin Tsou, Yu-Sheng Chao. Dipicolylamine derivatives and their pharmaceutical uses, PCT patents filed May 18, 2015.
  24. Chiung-Tong Chen, Kak-Shan Shia, Chien-Huang Wu, Lun Kelvin Tsou, Yu-Sheng Chao. 二甲基吡啶胺衍生物及其醫藥用途, Taiwan ROC patent filed May 19, 2015.
  25. Kak-Shan Shia, Jiing-Jyh Jan, Lun Kelvin Tsou, Chiung-Tong Chen, Yu-Sheng Chao Heterocyclic compounds and use thereof, US patent filed on September 21, 2015.
  26. Kak-Shan Shia, Jiing-Jyh Jan, Lun Kelvin Tsou, Chiung-Tong Chen, Yu-Sheng Chao Heterocyclic compounds and use thereof, PCT filed on September 21, 2015.
  27. 夏克山,詹景智,鄒倫,陳炯東,趙宇生. 雜環化合物及其用途, Taiwan ROC, filed on September 22, 2015.

Comments are closed.